Movano Inc. Form 10-Q Summary
Registrant identity: The supplied filing is for Movano Inc. (Nasdaq: MOVE), not Corvex, Inc. Verify that this is the intended filing.
Business context and reporting period
This is Movano’s unaudited quarterly report for the three months ended March 31, 2021, compared with the three months ended March 31, 2020. Movano is a development-stage health technology company developing RF-based wearables intended to measure health data, including glucose, blood pressure and heart rate. It had not generated operating revenue.
Financial results and liquidity
- Revenue and margins: No operating revenue was reported; operating and profit margins are therefore not meaningful.
- Operating expenses: $3.266 million, up from $2.019 million. Research and development was $1.942 million versus $1.501 million; general and administrative expense was $1.324 million versus $0.518 million.
- Losses: Operating loss was $3.266 million versus $2.019 million. Net loss was $5.608 million versus $2.025 million. After $2.489 million of preferred-stock accretion and dividends, net loss attributable to common stockholders was $8.097 million versus $3.981 million. Basic and diluted loss per share was $1.01 versus $1.58.
- Cash flow: Operating cash use was $4.040 million, compared with $2.223 million. Investing cash use was $0.011 million. Financing provided $45.095 million, primarily from the IPO. Cash increased $41.044 million to $46.754 million.
- Balance sheet and liquidity: At March 31, cash and equivalents were $46.754 million; current assets were $49.152 million and current liabilities $1.672 million. Total assets were $49.411 million, total liabilities $2.129 million, and stockholders’ equity $47.282 million. Accumulated deficit was $48.603 million.
- Debt and capital: Convertible notes and accrued interest totaling approximately $12.9 million converted into common stock at the IPO; no convertible notes remained on the March 31 balance sheet. The PPP loan remained outstanding, with $323,000 current and $28,000 noncurrent. Preferred stock also converted into common stock at the IPO.
Material changes versus the prior comparable period
- The March IPO sold 9,775,000 shares at $5.00 per share. The filing reports net proceeds of $44.3 million after underwriting and offering expenses; cash-flow financing proceeds from the IPO are shown as $45.019 million.
- Cash rose from $5.710 million at December 31, 2020 to $46.754 million at March 31, 2021. The IPO and conversions materially changed the company’s capital structure: common shares outstanding increased to 32,772,060, and redeemable preferred stock was eliminated.
- Operating expenses increased $1.247 million year over year, reflecting company growth and activity. Net loss also increased, including $0.883 million of interest expense and a $1.581 million noncash warrant fair-value expense in 2021.
Outlook, commentary, risks and unusual items
- Management expects significant expenses and increasing operating losses for at least several years. It believes March 31 cash will fund projected operating needs for at least 12 months, but not completion of product development and commercialization; additional financing may be needed.
- Key execution risks include proving the wearable’s accuracy and feasibility, completing development and clinical work, obtaining FDA and FCC clearance or approval, commercializing the product, and securing third-party manufacturing and distribution partners. The company had not demonstrated specified glucose or blood-pressure accuracy in studies described in the filing.
- The company reported three material weaknesses in internal control: insufficient segregation of duties, ineffective IT security and access controls, and insufficient precision in control design. Management concluded disclosure controls were ineffective as of March 31, 2021.
- The PPP loan’s forgiveness was uncertain; the company said it believed proceeds met forgiveness conditions but could not assure forgiveness. Management reported no pending legal matter believed likely to have a material adverse effect.
- COVID-19’s long-term business impact was uncertain. Other disclosed risks include competition, dependence on key personnel and consultants, intellectual-property protection, dilution, and potential need for further capital.
- Subsequent events included an April 2021 office lease with a 40-month term and approximately $14,000 monthly base rent for the first year, grants of 395,000 options to new employees, and formation of a wholly owned Irish subsidiary.
Important facts for investors to verify
- Confirm the intended issuer: the provided metadata says Corvex, Inc., while the filing identifies Movano Inc.
- Reconcile IPO proceeds reported as $44.3 million net proceeds in the narrative versus $45.019 million IPO proceeds in the cash-flow statement.
- Assess cash runway against the company’s development and commercialization plans, anticipated spending, and need for additional financing.
- Track product validation, clinical evidence, regulatory pathway and timing, and whether manufacturing or commercialization partners are secured.
- Monitor remediation of the three material weaknesses and the status of PPP loan forgiveness.
- Consider dilution and potential overhang from outstanding options and warrants; the filing lists 7,646,102 shares reserved for warrants and options outstanding or available for grant.